On March 6, 2015, Janssen Biotech, Inc and New York University filed suit against Celltrion Healthcare Co., Ltd., Celltrion, Inc. and Hospira, Inc. in connection with Celltrion and Hospira's proposed biosimilar to Janssen's Remicade. The action is pending before Judge Wolf in the district of Massachusetts, where Celltrion previously dismissed its declaratory judgment action after Janssen's motion to dismiss was fully briefed. Patterson Belknap, along with Akin Gump, represents plaintiffs Janssen and NYU in this case.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
